Experiences with

Nivolumab

of nivolumab co-formulated with rHuPH20, compared with IV nivolumab in patients with advanced or metastatic ccRCC who have previously received systemic therapy.1 A total of 495 patients were randomly assigned to receive either subcutaneous nivolumab or IV nivolumab.

Patients received nivolumab (3 mg/kg) and ipilimumab (1 mg/kg) every three weeks for four cycles, followed by maintenance nivolumab therapy. The primary endpoint was the disease control rate exceeding six months.

Now have metastases to ureter ( not v usual) and am about to start more Folfox with Nivolumab for three months. Seems the prognosis depends on how well I respond to this treatment. Anyone with similar experience able to pass on any thoughts etc?? Thank you

Mark Linch presented results from the NEPTUNES (NCT03061539), a multi-centre two-cohort, biomarker-selected phase 2 trial evaluating Nivolumab (anti-PD1) and ipilimumab (anti-CTLA4) for metastatic prostate cancer with an immunogenic signature. Dr.

Nivolumab was given intravenously on the first day of each 28-day cycle.

Nivolumab (Opdivo): Nivolumab is another checkpoint inhibitor that targets PD-1. Like pembrolizumab, nivolumab has been studied in clinical trials for advanced prostate cancer, often in combination with other therapies.

It would be the solo drug for me, not the other arms of the trial which includes avastin and nivolumab in conjunction with trial drug. Thanks

-Patrick [1] https://pubmed.ncbi.nlm.nih.gov/38167882/ [2] https://en.wikipedia.org/wiki/Nivolumab

Depending on the results do we get access to some novel drugs like olapariv or nivolumab, etc, that might help us ? 🫠thanks, Manilo.

I also found an ongoing trial immunotherapy trial IMPACT (NCT03570619) which combines other drugs used for immunotherapy with CDK12 (ie: Nivolumab and Ipilimumab) Has anyone here in the community had success on either of these trials?

An encouraging Opdivo/Yervoy study was presented at ASCO recently, which gave me a little more hope for the future. https://www.onclive.com/view/nivolumab-ipilimumab-bests-nivolumab-in-ovarian-and-extra-renal-clear-cell-carcinomas Yervoy (ipilimumab) is an anti-CTLA-4, which apparently has higher risk

not yet tested for prostate cancer (I think) but still… “But two years after starting a treatment regimen that combined ruxolitinib with the checkpoint inhibitor nivolumab—a current standard of care—87% of patients were still alive, and 46% stopped exhibiting signs of cancer progression altogether.”

"No patients met the primary endpoint of complete PSA response; however, 4/19 (21%) patients had a PSA decline >50%. Median PSA doubling times were 5.9 months pretreatment, 25.6 months on-treatment (p=0.001), and 9.0 months in the subsequent year off-treatment. The overall median radiographic progression-free

NIVOLUMAB will shortly be assessed by the Scottish Medicine Consortium (SMC) for use in NHS Scotland in combination with platinum-based chemotherapy for the neoadjuvant treatment (this is treatment given before surgery) for resectable non-small cell lung cancer in adults.

NIVOLUMAB will shortly be assessed by the Scottish Medicine Consortium (SMC) for use in NHS Scotland in combination with platinum-based chemotherapy for the neoadjuvant (treatment given before surgery) for resectable non-small cell lung cancer in adults.

Hi My husband has mesothelioma and has been having immunotherapy (Ipilimumab and Nivolumab) every 3 weeks since early January this year.

The new plan is to combination of dual immunotherapy with two immunotherapy drugs nivolumab and ipilimumab. Has anyone gone through a similar journey when 1st line treatment didn't work and pivoted?

https://www.mdanderson.org/newsroom/neoadjuvant-immunotherapy-with-relatlimab-and-nivolumab-is-safe-and-effective-in-stage-3-melanoma.h00-159543690.html Nature link from article: https://www.nature.com/articles/s41586-022-05368-8

This research is based on a hypothesis that asks "[i]if combining nivolumab, a PD-1 blocking antibody, with the BTK inhibitor (BTKi) ibrutinib could potentiate tumor-cell killing."[/i] [i]"Patients received nivolumab every 2 weeks of a 4-week cycle for a maximum of 24 cycles.

Then added immune checkpoint inhibitor nivolumab. Since BAT causes DNA damage and genomic rearrangements, they wanted to see if the nivolumab, as an immune therapy (PD-1 inhibitor) might add to the efficacy of BAT.